Case study: Accelerating a first-in-human obesity program while staying data-ready

The obesity treatment landscape is evolving rapidly, with sponsors racing to differentiate novel mechanisms in a highly competitive market. For emerging biotech companies, early-phase execution must move quickly, without compromising regulatory rigor or data integrity.

When a sponsor initiated an early-phase obesity study under a multi-country EPS+ model, the mandate was clear: accelerate startup, deliver interim data under compressed timelines, and maintain flexibility as the program evolved.

A complex, adaptive design under milestone pressure

The study was designed as a randomized, placebo-controlled, early-phase dose-escalation study in participants with elevated BMI. The protocol incorporated cohort expansion flexibility and anticipated amendments, including potential multiple-ascending dose components as data emerged.

Regulatory approvals were required across multiple geographies, including Central Europe, the UK, and the United States. At the same time, interim data transfers were tied to external communications, creating intense milestone pressure.

Early execution would decide not only study success but the sponsor’s broader development trajectory.

Balancing speed with control across countries

Parexel implemented a sequenced activation strategy, bringing sites across Europe and North America online in a deliberate order to balance speed, oversight, and enrollment momentum. This sequencing enabled efficient dosing across regions while accelerating regulatory submissions and approvals across regions.

Because sites were selected by the sponsor, proactive CRO governance was critical. Parexel provided full operational oversight, medical monitoring, pharmacovigilance, site and vendor management, and coordinated oversight across early phase units and external sites.

Cross-functional governance meetings ensured continuous alignment with the sponsor’s evolving priorities, including fast-turn interim data deliverables and protocol amendment planning.

Addressing high screen-fail rates in a “healthy high-BMI Body Mass Index (BMI)” population

As expected in early obesity studies, screen-fail rates were significant. The protocol required participants with elevated BMI but minimal comorbidities, a narrow window in a metabolically complex population.

Parexel conducted a granular review of screen-fail drivers, identifying patterns across metabolic and laboratory screening parameters.  

In response, the team:

• Tightened pre-screening and structured questionnaires
• Leveraged internal volunteer databases
• Targeted lower-risk demographic segments
• Implemented a structured re-screen strategy for borderline participants

These refinements improved enrollment efficiency and protected dosing momentum. In one region alone, re-screening yielded additional eligible participants, critical in a cohort-driven design where every subject mattered.

Staying data-ready under compressed interim timelines

Mid-study, the sponsor needed accelerated interim data transfers aligned with external press timelines. Parexel mobilized cross-functional teams to complete source data verification and query resolution within an abbreviated window without compromising quality standards.
Simultaneously, the team supported U.S. activation and ensured dosing milestones were achieved before reaching protocol-defined dose limits, an important milestone for the sponsor’s development program.

Delivering momentum for what comes next

The study achieved multi-country approvals, sustained enrollment momentum, and delivered interim data on schedule. The operational model also provided the flexibility needed to support protocol amendments and future phase expansion.
For sponsors advancing novel obesity therapies, success in early-phase development requires more than speed. It requires strategic governance, adaptive planning, and disciplined data readiness.

This program* shows how an integrated early-phase strategic approach can accelerate development while maintaining control in a highly competitive therapeutic area.
 

*Details have been generalized to protect sponsor confidentiality.
 

Start a conversation

Return to Insights Center